Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | DGAT1 | O75907 | 3/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.40 |
| ▸ | P4HTM | Q9NXG6 | 2/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.39 |
| ▸ | MTOR | P42345 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25202900 | 0.85 | TRPV1 (0.52) | DGAT1TRPV1P4HTMPIK3CAMTOR | |
| SCHEMBL13002821 | 0.83 | ALDH1A1 (0.38) | ALDH1A1RAB9ASMN1; SMN2DGAT1TRPV1 | |
| SCHEMBL8278725 | 0.78 | RAB9A (0.43) | ALDH1A1RAB9ASMN1; SMN2MAPTKMT2A | |
| SCHEMBL27961398 | 0.77 | TRPV1 (0.59) | DGAT1TRPV1 | |
| SCHEMBL15962680 | 0.75 | TRPV1 (0.52) | ALDH1A1RAB9ASMN1; SMN2TRPV1P4HTM | |
| SCHEMBL4596038 | 0.75 | HCAR3 (0.59) | ALDH1A1P4HTMMAPT | |
| SCHEMBL3774058 | 0.74 | ALDH1A1 (0.72) | ALDH1A1RAB9ASMN1; SMN2MAPTKMT2A | |
| SCHEMBL30919458 | 0.73 | NPSR1 (0.57) | ALDH1A1RAB9ASMN1; SMN2P4HTMPIK3CA | |
| SCHEMBL2242286 | 0.73 | NPSR1 (0.57) | ALDH1A1RAB9ASMN1; SMN2P4HTMPIK3CA | |
| SCHEMBL17729302 | 0.73 | P4HTM (0.54) | ALDH1A1RAB9ASMN1; SMN2P4HTMKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7851473-B2 | Amide compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-12-14 | — | — | US | disclosed |
| US-20080312226-A1 | Amide Compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-12-18 | — | — | US | disclosed |
| EP-1813606-A1 | AMIDE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2007-08-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312226-A1 | Amide Compound | FAAH, FAAH2, CNR2 | ALDH1A1 353/4885RAB9A 1416/4885SMN1; SMN2 2454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.